Gene: BDKRB2

624
B2R|BK-2|BK2|BKR2|BRB2
bradykinin receptor B2
protein-coding
14q32.2
Ensembl:ENSG00000168398 MIM:113503 Vega:OTTHUMG00000171408 UniprotKB:P30411
NC_000014.9
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.971e-1 (AD)  5.028e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4905470chr14:96226874 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMPRSS130.666
GDNF0.626
ADAMTS150.61
FAM83G0.608
BDKRB10.599
RELB0.598
INHBA0.571
MATN20.568
SERPINB80.566
GALR10.564

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GABRG1-0.353
CABLES1-0.351
NDP-0.328
SLC15A2-0.325
EPHB1-0.312
DIAPH3-0.312
SLC39A12-0.306
GPAM-0.301
CDH20-0.3
FUT9-0.3

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB05038AnatibantSmall Molecule209733-45-9InvestigationalTarget
DB06196IcatibantSmall Molecule130308-48-4Approved|InvestigationalTarget
DB06549LabradimilSmall Molecule159768-75-9InvestigationalTarget
ID Drug Name Action PubMed
C04676015-acetyldeoxynivalenol15-acetyldeoxynivalenol results in increased expression of BDKRB2 mRNA23792671
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDKRB2 mRNA"27188386
C0352074-amino-2,6-dinitrotoluene"4-amino-2,6-dinitrotoluene affects the expression of BDKRB2 mRNA"21346803
C0123584-hydroxycyclophosphamide[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of BDKRB2 mRNA25833159
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDKRB2 mRNA"27188386
C081174A 81988BDKRB2 affects the susceptibility to A 8198810614985
D000082AcetaminophenAcetaminophen results in increased expression of BDKRB2 mRNA29067470
D000255Adenosine TriphosphateBenzbromarone inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
D000255Adenosine Triphosphateicatibant inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
D000255Adenosine TriphosphateIndomethacin inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
D000255Adenosine Triphosphate[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate20135098
D000255Adenosine Triphosphateverlukast inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
C016601afimoxifene[afimoxifene co-treated with 4-hydroxycyclophosphamide] affects the expression of BDKRB2 mRNA25833159
D000393Air PollutantsAir Pollutants analog results in decreased expression of BDKRB2 mRNA21757418
C004471allyl isothiocyanateBDKRB2 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]17571167
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of BDKRB2 mRNA21298039
D017311AmlodipineBDKRB2 results in increased susceptibility to Amlodipine10523327
D001262AtenololBDKRB2 exon polymorphism affects the susceptibility to Atenolol12640257
D001285AtropineBDKRB2 affects the susceptibility to [Propranolol co-treated with Atropine]10614985
C069620B 3824B 3824 binds to and results in decreased activity of BDKRB2 protein1334354
C053748B 4162B 4162 binds to and results in decreased activity of BDKRB2 protein16473424
C044946benazeprilbenazepril results in increased activity of BDKRB2 protein15339989
C044946benazepril[icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril16982965
D001553BenzbromaroneBenzbromarone inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to BDKRB2 promoter]19654925
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BDKRB2 mRNA19619570
D004958EstradiolEstradiol results in increased expression of BDKRB2 mRNA19619570
C006780bisphenol Abisphenol A results in decreased expression of BDKRB2 mRNA25181051
C082229bradykinin, Lys-Leu(8)-desArg(9)-"bradykinin, Lys-Leu(8)-desArg(9)- affects the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]"17347322
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA20147733
D002118CalciumBDKRB2 protein affects the reaction [KNG1 protein affects the abundance of Calcium]18054572
D002118CalciumBDKRB2 protein affects the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]]16473424
D002118Calciumicatibant inhibits the reaction [[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium]22554775
D002118CalciumIndomethacin inhibits the reaction [[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium]22554775
D002118Calcium[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium22554775
D002118CalciumN-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium]22554775
C081643candesartancandesartan results in decreased expression of BDKRB2 mRNA18796534
D002211CapsaicinBDKRB2 affects the reaction [Capsaicin results in increased activity of TRPV1 protein]15363968
D002211CapsaicinBDKRB2 affects the reaction [KNG1 protein promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]]15363968
D002211CapsaicinCapsaicin inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]17347322
D002251Carbon TetrachlorideCarbon Tetrachloride results in decreased expression of BDKRB2 mRNA17484886
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of BDKRB2 protein18054572
D002108CeruletideCeruletide results in increased expression of BDKRB2 mRNA21484880
D002713Chlorine[Ozone co-treated with Chlorine] results in decreased expression of BDKRB2 mRNA18636392
D002809Chondroitin Sulfates[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates21436127
D019327Copper SulfateCopper Sulfate results in increased expression of BDKRB2 mRNA19549813
D003520CyclophosphamideCyclophosphamide affects the expression of BDKRB2 mRNA15576455
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of BDKRB2 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of BDKRB2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of BDKRB2 mRNA27392435
D002945CisplatinBDKRB2 gene mutant form inhibits the reaction [Cisplatin results in increased expression of IL1B mRNA]24975837
D002945CisplatinBDKRB2 gene mutant form inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]24975837
D002945CisplatinBDKRB2 gene mutant form results in decreased susceptibility to Cisplatin24975837
D002945CisplatinBDKRB2 gene results in increased susceptibility to Cisplatin24975837
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of BDKRB2 mRNA26924002
D004656EnalaprilEnalapril results in increased expression of BDKRB2 mRNA18190998
D004656EnalaprilEnalapril results in increased expression of BDKRB2 protein18190998
D005472FluorouracilTP53 protein affects the reaction [Fluorouracil results in increased expression of BDKRB2 mRNA]15016801
D004397FonofosFonofos results in increased methylation of BDKRB2 promoter22847954
D005557FormaldehydeFormaldehyde results in decreased expression of BDKRB2 mRNA20655997
C105311FR 173657FR 173657 binds to and results in decreased activity of BDKRB2 protein11104833
C105311FR 173657FR 173657 binds to BDKRB2 protein11815382
C105311FR 173657FR 173657 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]11104833
C105311FR 173657FR 173657 inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]11104833
C105311FR 173657FR 173657 binds to and results in decreased activity of BDKRB2 protein10666510
C105311FR 173657FR 173657 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C105311FR 173657FR 173657 inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]15140628
C105311FR 173657FR 173657 binds to and results in decreased activity of BDKRB2 protein10666510
C105311FR 173657FR 173657 binds to and results in decreased activity of BDKRB2 protein15838317
C107104FR 190997FR 173657 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]11104833
C107104FR 190997FR 190997 binds to and results in increased activity of BDKRB2 protein11104833
C107104FR 190997icatibant inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]11104833
C107104FR 190997MEN 11270 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]11104833
C107104FR 190997FR 173657 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C107104FR 190997FR 190997 binds to and results in increased activity of BDKRB2 protein15140628
C107104FR 190997icatibant inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C107104FR 190997LF 16-0687 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C107104FR 190997MEN 11270 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C102777gamma-mangostingamma-mangostin results in increased expression of BDKRB2 mRNA21440614
D019833Genistein[Genistein co-treated with Methoxychlor] results in increased expression of BDKRB2 mRNA21782745
D006152Cyclic GMP[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]16982965
D018738HexamethoniumBDKRB2 affects the susceptibility to Hexamethonium10614985
C065679icatibanticatibant binds to and results in decreased activity of BDKRB2 protein11104833
C065679icatibanticatibant binds to BDKRB2 protein11815382
C065679icatibanticatibant inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]11104833
C065679icatibanticatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]11104833
C065679icatibanticatibant inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
C065679icatibanticatibant binds to and results in decreased activity of BDKRB2 protein10666510
C065679icatibanticatibant inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C065679icatibanticatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]15140628
C065679icatibanticatibant binds to and results in decreased activity of BDKRB2 protein24975837
C065679icatibanticatibant binds to and results in decreased activity of BDKRB2 protein10666510|1272727
C065679icatibant[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates21436127
C065679icatibant[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Streptozocin17989505
C065679icatibant[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine17989505
C065679icatibanticatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]17347322
C065679icatibant[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]16982965
C065679icatibant[icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril16982965
C065679icatibant[icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Valsartan16982965
C065679icatibanticatibant binds to and results in decreased activity of BDKRB2 protein10737671|1075059
C065679icatibanticatibant inhibits the reaction [[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium]22554775
C065679icatibanticatibant results in decreased activity of BDKRB2 protein10498854|1557645
D007213IndomethacinIndomethacin inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
D007213IndomethacinIndomethacin inhibits the reaction [[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium]22554775
D007295Inositol Phosphates"bradykinin, Lys-Leu(8)-desArg(9)- affects the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]"17347322
D007295Inositol PhosphatesCapsaicin inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]17347322
D007295Inositol Phosphatesicatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]17347322
D007295Inositol Phosphates[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates17347322
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of BDKRB2 mRNA25613284
C081309irbesartanBDKRB2 exon polymorphism affects the susceptibility to irbesartan12640257
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of BDKRB2 mRNA27392435
C544151jinfukangjinfukang results in increased expression of BDKRB2 mRNA27392435
D0151216-Ketoprostaglandin F1 alphaBDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha16514058
D0151216-Ketoprostaglandin F1 alphaPD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha]16514058
C116248LF 16.0335LF 16.0335 binds to BDKRB2 protein11815382
C403051LF 16-0687LF 16-0687 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C403051LF 16-0687LF 16-0687 inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]15140628
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of BDKRB2 mRNA25613284
C018091maduramicinmaduramicin results in increased expression of BDKRB2 mRNA29128925
C119318MEN 11270MEN 11270 binds to and results in decreased activity of BDKRB2 protein11104833
C119318MEN 11270MEN 11270 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]11104833
C119318MEN 11270MEN 11270 inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]11104833
C119318MEN 11270MEN 11270 binds to and results in decreased activity of BDKRB2 protein10666510
C119318MEN 11270MEN 11270 inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]15140628
C119318MEN 11270MEN 11270 inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]15140628
C119318MEN 11270MEN 11270 binds to and results in decreased activity of BDKRB2 protein10666510
D008731Methoxychlor[Genistein co-treated with Methoxychlor] results in increased expression of BDKRB2 mRNA21782745
D008731MethoxychlorMethoxychlor results in increased expression of BDKRB2 mRNA21782745
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of BDKRB2 mRNA24810058
C517284monomethyl phthalatemonomethyl phthalate affects the expression of BDKRB2 mRNA26924002
C496401N-((3-(aminomethyl)phenyl)methyl)ethanimidamideN-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Calcium]22554775
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of BDKRB2 mRNA"23845593
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of BDKRB2 mRNA"25554681
D009532NickelNickel results in increased expression of BDKRB2 mRNA25583101
D009599NitroprussideBDKRB2 affects the susceptibility to Nitroprusside10614985
D009638NorepinephrineBDKRB2 affects the susceptibility to Norepinephrine12105144
C117759NPC 18884NPC 18884 binds to and results in decreased activity of BDKRB2 protein10543429
D010126Ozone[Ozone co-treated with Chlorine] results in decreased expression of BDKRB2 mRNA18636392
D010278ParathionParathion results in increased methylation of BDKRB2 promoter22847954
C073402PD 123319PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha]16514058
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in increased expression of BDKRB2 mRNA26705709
D020913PerindoprilPerindopril affects the expression of BDKRB2 protein18806609
D010634PhenobarbitalPhenobarbital affects the expression of BDKRB2 mRNA19159669
D010656PhenylephrineBDKRB2 affects the susceptibility to Phenylephrine10614985
D010656PhenylephrinePhenylephrine results in increased expression of BDKRB2 mRNA18158353
D010862PilocarpineBDKRB2 protein mutant form results in increased susceptibility to Pilocarpine15196965
D010936Plant ExtractsPlant Extracts results in decreased expression of BDKRB2 mRNA23557933
D059808PolyphenolsPolyphenols results in decreased expression of BDKRB2 mRNA16293270
D011192Potassium DichromatePotassium Dichromate results in increased expression of BDKRB2 mRNA23608068
D011433PropranololBDKRB2 affects the susceptibility to [Propranolol co-treated with Atropine]10614985
C513428pyrachlostrobinpyrachlostrobin results in increased expression of BDKRB2 mRNA27029645
C043940pyranoprofenBDKRB2 protein affects the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]]16473424
C052549ramiprilatBDKRB2 results in increased susceptibility to ramiprilat10523327
C059514resveratrolresveratrol results in decreased expression of BDKRB2 mRNA18089832
C059514resveratrolresveratrol results in decreased expression of BDKRB2 protein18089832
C089876RMP 7RMP 7 binds to and results in increased activity of BDKRB2 protein9525816
C094195S 16118S 16118 binds to and results in decreased activity of BDKRB2 protein12542457
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of BDKRB2 mRNA25895662
D013311StreptozocinStreptozocin results in increased expression of BDKRB2 mRNA19516248
D013311Streptozocin[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Streptozocin17989505
C012568terbufosterbufos results in increased methylation of BDKRB2 promoter22847954
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased expression of BDKRB2 mRNA25172293
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BDKRB2 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of BDKRB2 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of BDKRB2 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of BDKRB2 mRNA11489354
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of BDKRB2 mRNA22298810
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of BDKRB2 mRNA25613284
C009495titanium dioxidetitanium dioxide affects the expression of BDKRB2 mRNA17656681
D014212TretinoinTretinoin results in increased expression of BDKRB2 mRNA23724009|2383079
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BDKRB2 mRNA"26179874
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BDKRB2 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of BDKRB2 mRNA24383497|2627250
D014635Valproic AcidValproic Acid results in increased methylation of BDKRB2 gene29154799
D000068756Valsartan[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]16982965
D000068756Valsartan[icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Valsartan16982965
D001335Vehicle EmissionsVehicle Emissions affects the methylation of BDKRB2 gene25560391
C059141verlukastverlukast inhibits the reaction [[KNG1 protein results in increased activity of BDKRB2 protein] which results in increased secretion of Adenosine Triphosphate]20135098
D014750Vincristine[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine17989505
C087374WIN 64338WIN 64338 binds to BDKRB2 protein11815382
D015032ZincZinc deficiency results in increased expression of BDKRB2 mRNA12672911

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0002020protease binding-IPI17077303  
GO:0004435phosphatidylinositol phospholipase C activity-TAS8302267  
GO:0004947bradykinin receptor activity-IDA17077303  
GO:0005515protein binding-IPI18672896  23597562  
GO:0031702type 1 angiotensin receptor binding-IPI10993080  
GO:0046982protein heterodimerization activity-IPI10993080  
GO ID GO Term Qualifier Evidence PubMed
GO:0006939smooth muscle contraction-IC17077303  
GO:0006954inflammatory response-IC17077303  
GO:0007166cell surface receptor signaling pathway-TAS7916737  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-TAS10653985  
GO:0007186G-protein coupled receptor signaling pathway-TAS-  
GO:0007204positive regulation of cytosolic calcium ion concentration-TAS10653985  
GO:0008015blood circulation-NAS7835885  
GO:0009651response to salt stress-IEA-  
GO:0019229regulation of vasoconstriction-IC17077303  
GO:0033137negative regulation of peptidyl-serine phosphorylation-IEA-  
GO:0042310vasoconstriction-IEA-  
GO:0042311vasodilation-IEA-  
GO:0043114regulation of vascular permeability-IC17077303  
GO:0050482arachidonic acid secretion-IDA17077303  
GO:1902239negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005768endosome-IDA17077303  
GO:0005886plasma membrane-IDA17077303  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-TAS7916737  
KEGG ID KEGG Term
hsa04020Calcium signaling pathway
hsa04080Neuroactive ligand-receptor interaction
hsa04610Complement and coagulation cascades
hsa04810Regulation of actin cytoskeleton
hsa05142Chagas disease (American trypanosomiasis)
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-373076Class A/1 (Rhodopsin-like receptors)TAS
R-HSA-375276Peptide ligand-binding receptorsTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-416476G alpha (q) signalling eventsTAS
R-HSA-418594G alpha (i) signalling eventsTAS
R-HSA-500792GPCR ligand bindingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28469421Gene Variant of the Bradykinin B2 Receptor Influences Pulmonary Arterial Pressures in Heart Failure Patients. (2009)Olson TPClin Med Circ Respirat Pulm Med
20957051Gene Variant of the Bradykinin B2 Receptor Influences Pulmonary Arterial Pressures in Heart Failure Patients. (2009 Feb 17)Olson TPClin Med Circ Respirat Pulm Med